nach oben

Erschienen in:

13.02.2024 | Research

Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype

verfasst von: Antonio Dono, Jose Torres, Luis Nunez, Octavio Arevalo, Juan Carlos Rodriguez-Quinteros, Roy F. Riascos, Arash Kamali, Nitin Tandon, Leomar Y. Ballester, Yoshua Esquenazi

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Recent studies have identified that glioblastoma IDH-wildtype consists of different molecular subgroups with distinct prognoses. In order to accurately describe and classify gliomas, the Visually AcceSAble Rembrandt Images (VASARI) system was developed. The goal of this study was to evaluate the VASARI characteristics in molecular subgroups of IDH-wildtype glioblastoma.

Methods

A retrospective analysis of glioblastoma IDH- wildtype with comprehensive next-generation sequencing and pre-operative and post-operative MRI was performed. VASARI characteristics and 205 genes were evaluated. Multiple comparison adjustment by the Bejamin-Hochberg false discovery rate (BH-FDR) was performed. A 1:3 propensity score match (PSM) with a Caliper of 0.2 was done.

Results

178 patients with GBM IDH-WT met the inclusion criteria. 4q12 amplified patients (n = 20) were associated with cyst presence (30% vs. 12%, p = 0.042), decreased hemorrhage (35% vs. 62%, p = 0.028), and non-restricting/mixed (35%/60%) rather than restricting diffusion pattern (5%), meanwhile, 4q12 non-amplified patients had mostly restricting (47.4%) rather than a non-restricting/mixed diffusion pattern (28.4%/23.4%). This remained statistically significant after BH-FDR adjustment (p = 0.002). PSM by 4q12 amplification showed that diffusion characteristics continued to be significantly different. Among RB1-mutant patients, 96% had well-defined enhancing margins vs. 70.6% of RB1-WT (p = 0.018), however, this was not significant after BH-FDR or PSM.

Conclusions

Patients with glioblastoma IDH-wildtype harboring 4q12 amplification rarely have restricting DWI patterns compared to their wildtype counterparts, in which this DWI pattern is present in ~ 50% of patients. This suggests that some phenotypic imaging characteristics can be identified among molecular subtypes of IDH-wildtype glioblastoma.

Nur mit Berechtigung zugänglich

Ostrom QT, Price M, Neff C et al (2022) CBTRUS Statistical Report: primary brain and other Central Nervous System tumors diagnosed in the United States in 2015–2019. Neuro Oncol 24:v1–v95. https://doi.org/10.1093/neuonc/noac202CrossRefPubMedPubMedCentral

Dono A, Ramesh AV, Wang E et al (2021) The role of RB1 alteration and 4q12 amplification in IDH-WT Glioblastoma. https://doi.org/10.1093/noajnl/vdab050. Neurooncol Adv

Reardon DA, Brandes AA, Omuro A et al (2020) Effect of Nivolumab vs Bevacizumab in patients with recurrent Glioblastoma the CheckMate 143 phase 3 Randomized Clinical Trial. 5450:1–8. https://doi.org/10.1001/jamaoncol.2020.1024

Karschnia P, Dono A, Young JS et al (2023) Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: a report of the RANO resect group. Neuro Oncol. https://doi.org/10.1093/neuonc/noad074CrossRefPubMedPubMedCentral

Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in Gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710CrossRefPubMedPubMedCentral

Brennan CW, Verhaak RGW, McKenna A et al (2013) The somatic genomic Landscape of Glioblastoma. Cell 155:462–477. https://doi.org/10.1016/j.cell.2013.09.034CrossRefPubMedPubMedCentral

Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279CrossRefPubMedPubMedCentral

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106CrossRefPubMedPubMedCentral

Diplas BH, He X, Brosnan-Cashman JA et al (2018) The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun 9:1–11. https://doi.org/10.1038/s41467-018-04448-6CrossRef

10.

Galbraith K, Kumar A, Abdullah KG et al (2020) Molecular correlates of Long Survival in IDH-Wildtype Glioblastoma cohorts. 79:843–854. https://doi.org/10.1093/jnen/nlaa059

11.

Wangaryattawanich P, Hatami M, Wang J et al (2015) Multicenter imaging outcomes study of the Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. Neuro Oncol 17:1525–1537. https://doi.org/10.1093/neuonc/nov117CrossRefPubMedPubMedCentral

12.

Gutman DA, Cooper LAD, Hwang SN et al (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267:560–569. https://doi.org/10.1148/radiol.13120118CrossRefPubMedPubMedCentral

13.

VASARI Research Project. https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project

14.

Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https://doi.org/10.1016/j.jbi.2019.103208CrossRefPubMedPubMedCentral

15.

Dono A, Wang E, Lopez-Rivera V et al (2020) Molecular characteristics and clinical features of multifocal glioblastoma. J Neurooncol 148. https://doi.org/10.1007/s11060-020-03539-z

16.

Esquenazi Y, Friedman E, Liu Z et al (2017) The survival advantage of Supratotal Resection of Glioblastoma using selective cortical mapping and the subpial technique. Neurosurgery 81:275–288. https://doi.org/10.1093/neuros/nyw174CrossRefPubMed

17.

Chavhan GB, AlSabban Z, Babyn PS (2014) Diffusion-weighted imaging in Pediatric Body MR Imaging: principles, technique, and emerging applications. Radiographics 34:E73–E88. https://doi.org/10.1148/rg.343135047CrossRefPubMed

18.

Frampton GM, Fichtenholtz A, Otto GA et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023–1031. https://doi.org/10.1038/nbt.2696CrossRefPubMedPubMedCentral

19.

Schwaederle M, Krishnamurthy N, Daniels GA et al (2018) Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: a clinical and molecular analysis of 423 patients. Cancer 124:1288–1296. https://doi.org/10.1002/cncr.31175CrossRefPubMed

20.

Dono A, Mitra S, Shah M et al (2021) PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. J Neurooncol 153:153–160. https://doi.org/10.1007/s11060-021-03755-1CrossRefPubMedPubMedCentral

21.

Dono A, Amsbaugh M, Martir M et al (2021) Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma. J Neurooncol. https://doi.org/10.1007/s11060-020-03689-0CrossRefPubMedPubMedCentral

22.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244CrossRefPubMed

23.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

24.

Zhou H, Vallières M, Bai HX et al (2017) MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 19:862–870. https://doi.org/10.1093/neuonc/now256CrossRefPubMedPubMedCentral

25.

Park YW, Han K, Ahn SS et al (2018) Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. Am J Neuroradiol 39:37–42. https://doi.org/10.3174/ajnr.A5421CrossRefPubMedPubMedCentral

26.

Jain R, Johnson DR, Patel SH et al (2020) Real world use of a highly reliable imaging sign: T2-FLAIR mismatch for identification of IDH mutant astrocytomas. Neuro Oncol 1–8. https://doi.org/10.1093/neuonc/noaa041

27.

Booth TC, Williams M, Luis A et al (2020) Machine learning and glioma imaging biomarkers. Clin Radiol 75:20–32. https://doi.org/10.1016/j.crad.2019.07.001CrossRefPubMed

28.

Peeken JC, Hesse J, Haller B et al (2018) Semantic imaging features predict disease progression and survival in glioblastoma multiforme patients. Strahlenther Onkol 194:580–590. https://doi.org/10.1007/s00066-018-1276-4CrossRefPubMed

29.

Mazurowski MA, Desjardins A, Malof JM (2013) Imaging descriptors improve the predictive power of survival models for glioblastoma patients. Neuro Oncol 15:1389–1394. https://doi.org/10.1093/neuonc/nos335CrossRefPubMedPubMedCentral

30.

Drake LR, Hillmer AT, Cai Z (2020) Approaches to PET imaging of glioblastoma. Molecules 25. https://doi.org/10.3390/molecules25030568

31.

Karschnia P, Young JS, Dono A et al (2023) Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol 25:940–954. https://doi.org/10.1093/neuonc/noac193CrossRefPubMed

32.

Romano A, Palizzi S, Romano A et al (2023) Diffusion weighted imaging in Neuro-Oncology: Diagnosis, post-treatment changes, and advanced Sequences-An updated review. Cancers (Basel) 15. https://doi.org/10.3390/cancers15030618

33.

Svolos P, Kousi E, Kapsalaki E et al (2014) The role of diffusion and perfusion weighted imaging in the differential diagnosis of cerebral tumors: a review and future perspectives. Cancer Imaging 14:20. https://doi.org/10.1186/1470-7330-14-20CrossRefPubMedPubMedCentral

34.

Gaddamanugu S, Shafaat O, Sotoudeh H et al (2022) Clinical applications of diffusion-weighted sequence in brain imaging: beyond stroke. Neuroradiology 64:15–30. https://doi.org/10.1007/s00234-021-02819-3CrossRefPubMed

35.

Wang Q-P, Lei D-Q, Yuan Y, Xiong N-X (2020) Accuracy of ADC derived from DWI for differentiating high-grade from low-grade gliomas: systematic review and meta-analysis. Medicine 99:e19254. https://doi.org/10.1097/MD.0000000000019254CrossRefPubMedPubMedCentral

36.

Ikeda K, Kolakshyapati M, Takayasu T et al (2022) Diffusion-weighted imaging-gadolinium enhancement mismatch sign in diffuse midline glioma. Eur J Radiol 147:110103. https://doi.org/10.1016/j.ejrad.2021.110103CrossRefPubMed

37.

Holtkamp N, Ziegenhagen N, Malzer E et al (2007) Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro Oncol 9:291–297. https://doi.org/10.1215/15228517-2007-009CrossRefPubMedPubMedCentral

38.

Bleeker FE, Molenaar RJ, Leenstra S (2012) Recent advances in the molecular understanding of glioblastoma. J Neurooncol 108:11–27. https://doi.org/10.1007/s11060-011-0793-0CrossRefPubMedPubMedCentral

39.

Hamberg P, Verweij J, Sleijfer S (2010) (Pre-)Clinical pharmacology and activity of Pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15:539–547. https://doi.org/10.1634/theoncologist.2009-0274CrossRefPubMedPubMedCentral

40.

Burford A, Little SE, Jury A et al (2013) Distinct phenotypic differences Associated with Differential amplification of receptor tyrosine kinase genes at 4q12 in Glioblastoma. PLoS ONE 8. https://doi.org/10.1371/journal.pone.0071777

41.

Chi AS, Sorensen AG, Jain RK, Batchelor TT (2009) Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14:621–636. https://doi.org/10.1634/theoncologist.2008-0272CrossRefPubMed

42.

Joensuu H, Puputti M, Sihto H et al (2005) Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 207:224–231. https://doi.org/10.1002/path.1823CrossRefPubMed

43.

Nobusawa S, Stawski R, Kim YH et al (2011) Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Neuropathology 31:583–588. https://doi.org/10.1111/j.1440-1789.2011.01204.xCrossRefPubMed

44.

Meyer H-J, Wienke A, Surov A (2019) Association between VEGF expression and diffusion weighted imaging in several Tumors-A systematic review and Meta-analysis. Diagnostics (Basel) 9. https://doi.org/10.3390/diagnostics9040126

45.

Zhang L, Cheng C, Li B et al (2022) Combined clinical features and MRI parameters for the prediction of VEGFR2 in hepatocellular carcinoma patients. Front Oncol 12:961530. https://doi.org/10.3389/fonc.2022.961530CrossRefPubMedPubMedCentral

46.

Wang Y, Wang K, Li H et al (2015) Identifying the association of contrast enhancement with vascular endothelia growth factor expression in anaplastic gliomas: a volumetric magnetic resonance imaging analysis. PLoS ONE 10:e0121380. https://doi.org/10.1371/journal.pone.0121380CrossRefPubMedPubMedCentral

47.

Sun Z, Li Y, Wang Y et al (2019) Radiogenomic analysis of vascular endothelial growth factor in patients with diffuse gliomas. Cancer Imaging 19:68. https://doi.org/10.1186/s40644-019-0256-yCrossRefPubMedPubMedCentral

48.

Beig N, Patel J, Prasanna P et al (2018) Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Sci Rep 8:7. https://doi.org/10.1038/s41598-017-18310-0CrossRefPubMedPubMedCentral

49.

Kickingereder P, Götz M, Muschelli J et al (2016) Large-scale Radiomic Profiling of Recurrent Glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response. Clin Cancer Res 22:5765–5771. https://doi.org/10.1158/1078-0432.CCR-16-0702CrossRefPubMedPubMedCentral

Titel: Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype
verfasst von: Antonio Dono
Jose Torres
Luis Nunez
Octavio Arevalo
Juan Carlos Rodriguez-Quinteros
Roy F. Riascos
Arash Kamali
Nitin Tandon
Leomar Y. Ballester
Yoshua Esquenazi
Publikationsdatum: 13.02.2024
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 1/2024
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-024-04575-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery

Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes

The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab

CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas